Key result
Implantation of the Tricento transcatheter heart valve in a 74-year-old woman with severe tricuspid regurgitation reduced caval vein regurgitant volume and led to clinical improvement at 3 months.
Why the study?
Does the Tricento transcatheter heart valve improve symptoms and reduce regurgitant volume in patients with severe tricuspid regurgitation?
Case Report (n=1)
Does the Tricento transcatheter heart valve improve symptoms and reduce regurgitant volume in patients with severe tricuspid regurgitation?
The first-in-man implantation of the Tricento transcatheter heart valve demonstrates procedural feasibility and early clinical improvement for severe tricuspid regurgitation.
Answers are grounded in this paper and cite their sources.
First-in-human Tricento implantation shows short-term TR improvement; hypothesis-generating and requires prospective trials before adoption.
Here we describe the first implantation of the novel bicavally anchored Tricento transcatheter heart valve via the transvenous transfemoral access in a 74-year-old woman with severe tricuspid regurgitation and holosystolic hepatic vein backflow. Following successful implantation, caval vein regurgitant volume was reduced leading to symptomatic and clinical improvement at three-month follow-up. The Tricento device represents a promising, novel therapeutic option for patients with severe tricuspid regurgitation who are not candidates for open heart surgery.
No takes yet. Share an insight, caveat, or question.
Toggweiler et al. (2018) conducted a case report in Severe tricuspid regurgitation (n=1). Tricento transcatheter heart valve was evaluated on Caval vein regurgitant volume and symptomatic/clinical improvement. Implantation of the Tricento transcatheter heart valve in a 74-year-old woman with severe tricuspid regurgitation reduced caval vein regurgitant volume and led to clinical improvement at 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: